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Background: Antimicrobial peptides (AMPs) such as cathelicidins contribute to initial defense of the airway against inhaled pathogens.
Recent studies have shown that the hormonally active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) up-regulates AMP gene
expression in several established cell lines. Furthermore, serum levels of vitamin D are often deficient in cystic fibrosis (CF) patients.
Methods: We investigated the effect of 1,25(OH)2D3 on AMP mRNA levels in primary cultures of normal human bronchial epithelial
(NHBE) cells by real-time PCR, and protein levels by Western blot. Antimicrobial activity of airway surface fluid from these cells was
measured by in vitro assay against laboratory strains of bacteria.
Results: Treatment of NHBE cells with 1,25(OH)2D3 (10
-8M), resulted in a 10-fold up-regulation of cathelicidin mRNA levels after 12 h,
which was augmented 2-fold with co-incubation of 1 mM Calcium. Moreover, 1,25(OH)2D3 induced antimicrobial activity against the airway
pathogens Bordetella bronchiseptica and Pseudomonas aeruginosa. 1,25(OH)2D3 induced cathelicidin mRNA expression equally in both
normal and CF bronchial epithelial cells.
Conclusions: Elucidation of the effect of 1,25(OH)2D3 on cathelicidin expression in NHBE cells and CF bronchial epithelial cells will aid in
the development of novel therapeutic agents for treatment of airway infections in CF.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Innate immunity; Vitamin D; Antimicrobial peptide; Airway surface fluid1. Introduction
The airway epithelium is constantly encountered by
pathogens present in ambient air, and a complex defense
system containing antimicrobial components has evolved to
prevent microbial colonization. These antimicrobial compo-
nents are present in airway surface fluid (ASF), which include
larger proteins such as lysozyme and lactoferrin, as well as the
defensins and cathelicidins [1,2]. Human cathelicidin is a
cationic antimicrobial peptide (AMP) also known as hCAP18/
LL-37. Structurally, all cathelicidins consist of an N-terminal
signal sequence, followed by conserved cathelin-like prodo-
main and variable antimicrobial domain [3,4]. The human⁎ Corresponding author. Tel.: +1 973 972 3324; fax: +1 973 972 0045.
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doi:10.1016/j.jcf.2007.03.003precursor peptide is processed by proteolytic cleavage to
release the antimicrobial domain, called LL-37 [5]. It exhibits
broad spectrum antimicrobial activity against microbes
including Gram-positive and Gram-negative bacteria as well
as fungi and certain viruses [6]. LL-37 was initially identified
in the specific granules of neutrophils, and expression was
subsequently identified in monocytes, T cells, and in various
epithelia [1,7,8].
While initially isolated as an antimicrobial peptide, LL-37
has been discovered to exhibit numerous other activities,
including chemotactic activity for neutrophils, monocytes and
some T cells [9], and induction of IL-8 secretion from
epithelial cell lines [10]. Furthermore, LL-37 affects dendritic
cell (DC) maturation, and can act synergistically with the DC
maturation cytokine GM-CSF to activate signal transduc-
tion pathways in monocytes [11]. Together, these multipleed by Elsevier B.V. All rights reserved.
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important, multifunctional role in host defense.
The increasing development of antibiotic resistant bac-
teria, especially as seen in cystic fibrosis (CF) airway infec-
tion [13] has demonstrated the need for more efficient
antibiotic therapies. Since bacteria do not generally develop
resistance to AMPs such as LL-37, they have been proposed
as useful therapeutics [13–16], however technical difficulties
in their large-scale production and use as direct antimicrobial
agents make them less attractive as therapies [17,18]. Ex-
pression of the LL-37 gene can be induced by LPS and
interleukin (IL)-1α [19], suggesting that its modulation by
exogenous agents could augment the natural innate immune
defense against infections.
Recently it was demonstrated that the hormonally active
form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3),
induced AMPs in number of established cell lines as well as
keratinocytes andmyeloid cells at concentrations from10−9 M
to 10−7 M [20–23]. However, the effect of 1,25(OH)2D3 on
cathelicidin gene expression in primary cultures of airway cells
has not been studied. This is important as deficiencies in serum
25-hydroxyvitamin D3 levels have been observed in patients
with CF [24], suggesting that exogenous regulation of this
AMP gene could lead to antimicrobial therapies.
In this study, we examine the induction of cathelicidin by
1,25(OH)2D3 in primary human bronchial epithelial cells and
the resultant increase in antimicrobial activity against airway
pathogens of the airway secretions. We also show the in-
creased cathelicidin expression by 1,25(OH)2D3 in CF bron-
chial epithelial cells, supporting the argument that 1,25
(OH)2D3 can augment antibacterial activity in airway epi-
thelia of CF patients, suggesting a novel potential therapy for
preventing and treating airway infections.
2. Material and methods
2.1. Tissue culture
Normal human bronchial epithelial (NHBE) cells (Bio-
Whittaker, Inc., Walkersville, MD, USA), AA (bronchial
cells with wt CFTR) and KK (bronchial cells with ΔF508
CFTR) cell lines were cultured in bronchial epithelial growth
medium (BEGM; BioWhittaker, Inc.) supplemented with
BPE, insulin, HC, retinoic acid, transferrin, triiodothyronine,
epinephrine, and hEGF. NHBE (passage-5), AA, or KK cells
were seeded onto 6-well tissue culture plate at a density of
0.35×106 cells/well and incubated overnight. Old medium
was removed, and fresh medium (2 ml) was added to each
well. Cells were incubated in the fresh media for 24 h prior to
vehicle (ethanol) or 1,25(OH)2D3 (10
-8M) treatment (to
deplete growth factors which might interfere in the treatment).
Cycloheximide (Sigma, St. Louis, MO, USA) was used at
20 μg/ml and added 30 min prior to the vehicle or 1,25
(OH)2D3 treatment. Actinomycin D (Sigma) was added at the
same time as vehicle or 1,25(OH)2D3 added [20]. The
synergistic role of calcium was determined by pretreatingcells with calcium chloride (1.0 mM) and incubated for 24 h
before vehicle or 1,25(OH)2D3. All cells were maintained at
37 °C in humidified atmosphere containing 5% CO2.
2.2. Messenger RNA analysis
2.2.1. Semi-quantitative RT-PCR
Total RNAwas prepared using QIAshredder and RNeasy
Mini Kit, treated with RNase-Free DNase Set (Qiagen,
Valencia, CA, USA). Five hundred nanograms of total RNA
was reverse transcribed with Superscript III reverse tran-
scriptase by oligo(dT) primers in 20 μl as described by the
manufacturer (Invitrogen, Carlsbad, California, USA). First-
stranded cDNA was amplified by PCR. PCR primer set for
cathelicidin consisted of forward: 5′-GTGACTTCAAGAA-
GGACGGG-3′; reverse: 5′-GGGTAGGGCACACACTA-
GGA-3′ and amplified a product of 238 bp. β-Actin was
amplified in each reaction using following primer set: for-
ward, 5′-AGTCCTGTGGCATCCACGAAACTA-3′; reverse
5′-CTTCTGCATCCTGTCGGCAATG-3′ and amplified a
product of 138 bp. Each PCR reaction contained 3 mM of
Mg2+, 0.2 mM of dNTP, 0.4 μl of 5 u/μl Taq polymerase
(Invitrogen), and 200 pM of primers. After an initial dena-
turing step (95 °C for 1 min) 30 cycles of denaturing (94 °C for
1 min), annealing (60 °C for 1 min), and extension (72 °C for
1 min), followed by 7 min at 72 °C for final extension were
conducted. PCRproductswere electrophoresed on 2%agarose
gel containing ethidium bromide.
2.2.2. Real-time quantitative PCR (RTQ-PCR)
hBD-1, hBD-2, hBD-3, and cathelicidin mRNA levels
were quantified by real-time PCR using MyCycler (Bio-
Rad Laboratories, Hercules, CA, USA). A total of 1 μl of
cDNA (described above) was analyzed using the final
concentration of 100 nM of primers, 2× SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA)
in volume of 20 μl. RTQ-PCR primers used were: cathelicidin
forward, 5′-GTCACCAGAGGATTGTGACTTCAA-3′, and
reverse, 5′-TTGAGGGTCACTGTCCCCATA-3′; hBD-1 for-
ward, 5′-CGCCATGAGAACTTCCTACCTTCTG-3′, and
reverse, 5′-GAATAGAGACATTGCCCTCCACTGC-3′;
hBD-2 forward, 5′-GATGCCTCTTCCAGGTGTTTTTGG-
3′, and reverse, 5′-TTGTTCCAGGGAGACCACAGGTG-3′;
hBD-3 forward, 5′-TATCTTCTGTTTGCTTTGCTCTTC-3′,
and reverse, 5′-CCTCTGACTCTGCAATAATATTTCTG-
TAA-3′; β-actin forward, 5′-AGTCTGTGGCATCCAC-
GAAACTAC-3′, and reverse, 5′-CTTCTGCATCCTG-
TCGGCAATG-3′; and β2-microglobulin (B2M) forward,
5′-CTCCGTGGCCTTAGCTGTG-3′, and reverse, 5′-TTT-
GGAGTACGCTGGATAGCCT-3′. The PCR fragments were
amplified for 45 cycles (15 s at 95 °C and 1 min at 60 °C). The
relative for mRNA expression in each sample was calculated
based on its Ct value comparison to Ct of housekeeping gene.
The data were presented as 2−ΔΔCt, an arbitrary unit. All
amplified products showed single peak in the dissociation
curve test. RTQ-PCR was performed in triplicates for each
Fig. 1. Induction of cathelicidin gene expression in NHBE cells. NHBE cells
were treated with 10−8M 1,25(OH)2D3 for times indicated. (A) Total RNA
was extracted, and RTQ-PCR was conducted to quantify hBD1, 2, 3, and
cathelicidin mRNA levels. (B) Kinetics of cathelicidin mRNA induction was
determined as described above. β-Actin was used as a house-keeping gene.
Results are represented as the means±SEM (⁎pb0.05) from at least three
independent experiments. (C) NHBE cells were treated with 10-8M 1,25
(OH)2D3 or with vehicle for 24 or 48 h. Total cell lysates were analyzed by
Western blot to observe hCAP18 expression. The amount of protein from the
lysates was determined by Bradford assay, and equal amount of protein was
loaded in each well, and a parallel blot was performed with an antibody to
β-actin. Lane 1, 24 h, vehicle; lane 2, 24 h, 1,25(OH)2D3; lane 3, 48 h, vehicle;
lane 4, 48 h, 1,25(OH)2D3.
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pendent experiments.
2.3. Protein expression analysis
Protein expression was analyzed byWestern blot. For LL-
37 expression analysis, total cell lysates were prepared and
concentration was measured by Bradford assay. Equal
amounts of protein from each sample were electrophoresed
through SDS-PAGE 8–18% gradient gels. The material in
gels was blotted onto a polyvinylidene difluoride (PVDF)
membrane (Bio-Rad), and the membrane was blocked with
3% BSA in pH 7.5 TBS buffer for 2 h. After washes (0.02%
Tween 20 pH 7.5 TBS), immunolabeling was performed
using polyclonal rabbit antibody against hCAP18/LL-37
(1:7500) or β-actin (1:7500) overnight. Alkaline phospha-
tase-conjugated goat anti rabbit IgG (LL-37, Sigma) or goat
anti-mouse (β-actin, Bio-Rad) was applied (1:5000) to the
membrane for 2 h after washes. The membrane was washed
several times for 3 h, and bound antibodies were visualized
by using AP conjugate substrate kit (Bio-Rad). Western blots
were repeated three times.
For vitamin D receptor (VDR) expression analysis, a
method from Barletta et al. was followed [25]. Briefly,
nuclear extracts were prepared following method of Legarda
et al. [26]. Protein concentration was measured by Bradford
assay. Equal amount of protein (40 μg) was electrophoresed
through a 10% SDS-polyacrylamide gel. Proteins were
transferred to a PVDF membrane, and the membrane was
blocked with PBST (0.5% Tween-20 in PBS) containing 5%
nonfat milk at 4 °C for 16 h. After blocking, the blot was
incubated with rabbit VDR polyclonal antibody (C-20, Santa
Cruz Biotechnology, 1:3000) for 2 h at room temperature,
followed by incubation for an additional hour with a goat
anti-rat IgG conjugated to horseradish peroxidase (Sigma).
After washing with PBST, the ECL Western blotting
detection system (NEN) was used to detect the antigen/
antibody complex. As a control, VDR Western blots were
also analyzed for α-tubulin (Sigma).
2.4. Preparation of airway surface fluid (ASF)
NHBE cells were plated at 0.3×106 cells/well onto
Transwell CM inserts (0.45-μm pore size and 24-mm
diameter; Costar, Cambridge, MA, USA). Fresh medium
was replaced every day with 1 ml on the apical and 2 ml on
the basolateral compartment until the cells were grown to
confluence. To treat the cells with 1,25(OH)2D3, the apical
surface medium was aspirated and washed with fresh
medium three times. 1,25(OH)2D3 (10
-8M final concentra-
tion) was added to the basolateral compartment, and cells
were further cultured. The crude ASF was then collected by
washing the apical surface of the cells with 140 μl of 10 mM
sodium phosphate buffer. The collected solution was
centrifuged at 200×g for 10 min, and supernatant was
recovered as ASF [27]. ASF was stored at −80 °C.2.5. Antimicrobial assay
The effect of 1,25(OH)2D3 treatment on the bactericidal
activity of ASF of NHBE cells was studied using Bordetella
Fig. 2. Mechanism of induction of cathelicidin in NHBE cells. NHBE cells
were pretreated in the absence (−CHX) or presence (+CHX) of
cycloheximide (20 μg/ml) for 30 min followed by 10−8M 1,25(OH)2D3.
Total RNA was extracted, and RTQ-PCR was conducted to determine
cathelicidin mRNA levels, normalized to β-actin. Graphs show means±
SEM (⁎pb0.05) from at least three experiments.
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Single colonies of P. aeruginosa were inoculated into LB
broth and B. bronchiseptica in Stainer–Scholte medium
(SSM) overnight. Aliquots of these cultures were transferred
into fresh LB broth and SSM and incubated 3–6 h to obtain
mid-log phase of the bacteria growth. 500 CFU of bacteria in
10μl of 10 mM of sodium phosphate buffer was mixed with
90 μl of ASF in a 1.5-ml tube, and the mixture was incubated
for 3 h at 37 °C while shaking at 75 rmp. P. aeruginosa was
seeded on LB plates overnight, and B. bronchiseptica onto
BG Bordet–Gengou (BG) agar plates (Difco Laboratories,
Detroit, MI, USA) supplemented with 5% sheep blood for
48 h. CFU were counted to determine activity.
2.6. Statistical analysis
Data are expressed as means±standard error of the mean
(SEM). Statistical analysis was performed using two-tailed,
unpaired Student's t-test using Microsoft Excel software.
Significance was accepted at Pb0.05.
3. Results
3.1. Induction of cathelicidin expression by 1,25(OH)2D3 in
NHBE cells
To assess the effect of 1,25(OH)2D3 on expression of
AMPs, NHBE cells were exposed to 10−8M 1,25(OH)2D3
for 0, 6, 24, and 48 h. Total RNA was collected and used
separately for cDNA synthesis. The cDNA was utilized as
templates in the RT-PCR and RTQ-PCR reactions for hBD1,
2, 3, and cathelicidin. β-Actin was used as a housekeeping
gene control. The PCR reactions were size fractionated on a
2% agarose gel, and the intensity of PCR products of
cathelicidin only was increased at 6 and 24 h of 1,25(OH)2D3
exposure (data not shown). To confirm the RT-PCR results,
RTQ-PCR was conducted for hBD1, 2, 3, and cathelicidin.
Fig. 1A shows that cathelicidin mRNA levels were up-
regulated whereas mRNA levels of hBD1, 2, and 3 remained
at a basal level.
To define the kinetics of cathelicidin mRNA induction in
response to 1,25(OH)2D3, NHBE cells were treated with
1,25(OH)2D3 in a time course as indicated. RTQ-PCR result
showed that the levels of cathelicidin mRNA were sig-
nificantly (pb0.05) up-regulated within 3 h of exposure,
with a maximum induction of 10-fold at 12 to 24 h of
incubation (Fig. 1B). Incubation with lower doses (10-9M
and below) failed to elicit a significant response (data not
shown).
To determine whether the induction of cathelicidin
mRNA levels correlated to an increase in protein expression,
Western blot analysis was performed. In this experiment,
NHBE cells were treated with vehicle or 1,25(OH)2D3, and
total cell lysates were collected for the Western blot. After 24
and 48 h of exposure, increased levels of hCAP18 peptide
were observed compared with the vehicle-treated sample(Fig. 1C). As with the initial description of this peptide in
lung extracts [8], two bands are observed. The larger band
may be attributed to the unprocessed precursor.
3.2. Mechanism of cathelicidin mRNA induction by 1,25
(OH)2D3 in NHBE cells
To test whether the induction of cathelicidin mRNA by
1,25(OH)2D3 requires new protein synthesis, NHBE cells
were pretreated with cycloheximide or vehicle prior to 1,25
(OH)2D3 addition to block the new protein expression. The
results (Fig. 2) demonstrated that cycloheximide pretreat-
ment inhibited ongoing cathelicidin mRNA induction by
1,25(OH)2D3, indicating that new protein synthesis is
necessary for cathelicidin mRNA induction by 1,25
(OH)2D3. Similarly, there was no induction observed when
1,25(OH)2D3 was co-incubated with 5μg/ml actinomycin D
(data not shown), suggesting that the induction is at the level
of transcription.
To determine whether VDR was expressed in NHBE
cells, nuclear extracts were prepared and Western blot anal-
ysis was conducted. The results (data not shown) demon-
strated that VDR is expressed in NHBE cells.
3.3. Synergistic role of calcium in cathelicidin mRNA
induction with 1,25(OH)2D3 in NHBE cells
Calcium interacts with vitamin D, regulating immune
processes including TNF-α production [31] and LL-37
expression [23]. To determine the effect of calcium with the
addition of 1,25(OH)2D3, we pretreated NHBE cells with
CaCl2 (1.0 mM) for 24 h prior to 1,25(OH)2D3 addition.
RTQ-PCR data showed that a 100% increase in cathelicidin
mRNA levels was observed when cells were pretreated with
calcium prior to 1,25(OH)2D3 addition compared with 1,25
(OH)2D3 administration alone at 6 h of 1,25(OH)2D3 ex-
posure. A 50% increased induction was observed at 24 h.
Fig. 3. Role of calcium in 1,25(OH)2D3-mediated induction of LL-37.
NHBE cells were pretreated with 1.0 mM CaCl2 (+calcium) or vehicle
(−calcium) for 24 h followed by 10−8M 1,25(OH)2D3 exposure for
increasing times. Total RNA was collected and RTQ-PCR was conducted.
Cathelicidin mRNA levels were determined by RTQ-PCR and normalized to
β-2-microglobulin. Results show means±SEM (⁎pb0.05) of three
independent experiments.
Fig. 4. Induction of antibiotic activity of airway surface fluid by 1,25(OH)2D3.
NHBE cells were grown on Transwell CM inserts and exposed to 10−8M 1,25
(OH)2D3 or vehicle basolaterally for 24 h. Antimicrobial activity of ASL
against B. bronchiseptica and P. aeruginosa was determined by counting the
number of colonies on 5% BG plates supplemented with 5% sheep blood and
LB plates, respectively, after incubation with the ASL collected from the
NHBE cells cultured above. (B) Inhibition of antimicrobial activity with LL-37
antibody. ASF was pretreated with 1 μl anti LL-37 antibody (gift of R. Gallo,
UCSD) or control serum for 1 h prior to addition of P. aeruginosa in
antimicrobial assays as described above. Results are reported as means±SEM
(⁎pb0.05) of at least three independent experiments.
Fig. 5. Induction of LL-37 mRNA in normal and CF cell lines. AA and KK
cell lines were grown to confluence and exposed to 10−8M 1,25(OH)2D3 for
0, 3, 6, 12, 24, and 48 h. Total RNA was extracted, and RTQ-PCR was
performed to determine cathelicidin mRNA levels. β-2-Microglobulin
primer sets were used for normalization. Results are represented as the
means±SEM (⁎pb0.05) from at least three independent experiments.
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cathelicidin mRNA level (Fig. 3). These results suggested
that calcium and 1,25(OH)2D3 have a synergistic role in
inducing cathelicidin mRNA. Higher concentrations of
calcium (up to 4 mM) with longer pre-incubation time (up
to 72 h) was administered to NHBE cells to examine the
maximum calcium effect; however, this resulted in a
decrease in cell viability, potentially due to calcium toxicity
(data not shown).
3.4. Induction of antimicrobial activity by 1,25(OH)2D3
against airway pathogens
To examine whether 1,25(OH)2D3 also induces antimi-
crobial activity against airway pathogens, NHBE cells were
grown in air–liquid interface cultures and treated with 1,25
(OH)2D3 or vehicle basolaterally for 24 h. ASF was collected
and bacteria were incubated with the ASF followed by
seeding on plates to obtain viable colonies. Our results
demonstrated that ASF from 1,25(OH)2D3-treated cells
exhibited increased antimicrobial activity, indicating cathe-
licidin up-regulation correlated with antibacterial activity
induction. This was observed with both B. bronchiseptica
and P. aeruginosa (Fig. 4A). Specifically, we observed up to
47% reduction in viable colonies of B. bronchiseptica and
50% reduction at P. aeruginosa after 24 h of induction.
To assess the contribution of LL-37 to this antimicrobial
activity, samples of ASF from cultures incubated with 1,25
(OH)2D3 or vehicle for 24 h were pre-incubated with either a
polyclonal antibody to LL-37 or control serum prior to the
assay. The results in Fig. 4B demonstrate a significant
decrease in the antimicrobial activity in those samples (both
stimulated and unstimulated) pre-incubated with the anti-
body compared with control serum. There was no significant
difference between the stimulated samples pre-incubated
with the antibody and the unstimulated samples pretreatedwith control serum. This indicates that at least a portion of
the activity that is induced in the airway surface fluid is due
to LL-37.
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and non-CF cell lines
Since bacterial infections in the airway are a major health
problem in CF patients, we examined whether 1,25(OH)2D3
could similarly induce cathelicidin expression in epithelial
cells exhibiting the CF defect. We stimulated two cell lines,
AA (bronchial cells with wt CFTR) and KK (bronchial cells
with the homozygous ΔF508 CFTR mutation), with 10-8M
1,25(OH)2D3. Total RNA was collected at increasing times,
and cDNA was synthesized for RT-PCR (data not shown)
and RTQ-PCR. The results shown in Fig. 5 demonstrate that
both normal and CF cell lines exhibited induction of
cathelicidin mRNA at the same levels. We observed the
up-regulation of cathelicidin mRNA as early as 3 h of
exposure, and a maximum induction of 15-fold at 12 h.
4. Discussion
Previous studies demonstrated cathelicidin induction by
physiological concentrations of 1,25(OH)2D3 in established
cell lines from keratinocytes, monocytes, myeloid leukemia
and airway submucosal gland, as well as head and neck
squamous cell carcinoma [20–23]. These studies were based
on the identification of VDRE consensus sequences in the 5′
flanking region of the hBD2 and LL-37 genes. In the current
study, we demonstrated that 1,25(OH)2D3 induced cathe-
licidin expression in primary cultures of bronchial epithelia.
In contrast to the previous results by Wang et al.
demonstrating induction of cathelicidin and hBD2 [22], we
observed that only cathelicidin mRNA and protein expres-
sion were up-regulated by 1,25(OH)2D3. This result
indicated that AMP induction by 1,25(OH)2D3 is differen-
tially regulated between cell types.
The mechanism that regulates the induction of cathe-
licidin expression by 1,25(OH)2D3 is still unclear. Recent
studies stressed the necessity of the VDRE in the cathelicidin
promoter region in the induction of cathelicidin gene ex-
pression by 1,25(OH)2D3 in several established cell lines
[20,22]. Our results demonstrate the presence of VDR in
bronchial epithelial cells, suggesting that a 1,25(OH)2D3
mechanism is present in these cells. However, Gombart et al.
demonstrated that ongoing protein synthesis is not necessary
for the induction of cathelicidin gene expression by 1,25
(OH)2D3 in U937 cells [20]. In contrast, we show that the
inhibition of new protein synthesis prior to 1,25(OH)2D3
addition prevented the induction of cathelicidin mRNA
(Fig. 2), indicating that cathelicidinmRNA induction by 1,25
(OH)2D3 requires new protein synthesis. This difference may
reflect the presence of multiple mechanisms for the activation
of cathelicidin gene expression in airway cells.
We first demonstrated that induction of antimicrobial
peptide gene expression in airway cells with LPS and other
inflammatory mediators [32], suggesting that modulation of
these genes could be used to increase the host defense
capability of the airway. The induction of endogenouscathelicidin expression by cytokines and growth factors has
been investigated in several cell lines. LPS and IL-1α treat-
ment of keratinocytes induced cathelicidin expression [19].
In addition, insulin-like growth factor-1 (IGF-1) and butyrate
are also known to induce cathelicidin expression in
keratinocytes and in colonic epithelial cells, respectively
[6,33,34]. However, these agents would not be good
candidates as therapeutics because they can be highly toxic
or are easily degraded in the physiological environment. 1,25
(OH)2D3 used in current research is a relatively safe mol-
ecule, and the amount used (10−8M) is also in the range of
the physiological environment that would not cause any
toxicity, and thus may represent the levels in normal
individuals. However, due to fact that vitamin D is absorbed
through the plasma membrane, it could be possible to
introduce the inducing agent apically, by inhalation of
vitamin D. This could allow for the targeted introduction of
higher doses without toxicity. Alternatively, one could use
analogs of 1,25(OH)2D3 that have been shown in in vivo
studies to induce VDR-mediated responses without causing
calcemia [35].
Our results demonstrated that ASF collected from 1,25
(OH)2D3-treated cells exhibited increased antibacterial
activity against airway pathogens (Fig. 4). While much of
this antimicrobial activity in the induced cultures could be
returned to baseline levels with a specific anti-LL-37 anti-
body, other genes involved in innate defense might also be
induced by 1,25(OH)2D3. The ability to induce the
expression of cathelicidin on the mucosal surface of bron-
chial epithelia could thus provide therapeutic benefits in
treating airway infections and disorders.
More than 90% of lung infections in CF are caused by
P. aeruginosa [13]. Moreover, there has been an increase in
multidrug-resistant CF pathogens including P. aeruginosa
[36], and a lack of new antibiotics to address these infections.
Thus, developing new therapeutics has become a vital need
for CF patients, and antimicrobial peptides and their
mimetics are extremely attractive candidates because of
their bactericidal activity against multidrug-resistant bacteria
[13,37]. Previous studies indicated that ASF from CF airway
epithelial cell cultures exhibited reduced antimicrobial
activity [30]. However, increased expression of cathelicidin
augmented bactericidal activity against P. aeruginosa in a
xenograft model of CF bronchial epithelium [38], suggesting
that regulation of cathelicidin could be used as part of an
antibiotic therapy for CF. Recent clinical studies demon-
strated that vitamin D deficiency is common among patients
with CF. This deficiency might be caused by poor absorption
of vitamin D and the lack of conversion of 25-hydroxyvi-
tamin D3 to 1,25(OH)2D3 [24,39,40]. Therefore, we hypo-
thesized that treatment of CF cultures with exogenous 1,25
(OH)2D3 would increase cathelicidin expression, which
would consequently increase bactericidal activity. Our
results indicated that cathelicidin expression could be
induced equally in both normal and CF bronchial epithelial
cells (Fig. 5), supporting our hypothesis that regulation of
409S. Yim et al. / Journal of Cystic Fibrosis 6 (2007) 403–410antimicrobial peptide gene expression may be useful to
augment current therapies to treat or prevent bacterial inf-
ections in CF airways.
Acknowledgements
The authors would like to thank Dr. Richard Gallo
(University of California, San Diego) for the LL-37 antibody
and Dr. Scott Randell (University of North Carolina, Chapel
Hill) for the AA and KK cell lines. This work was supported
by grants from the US Public Health Service, NIH 1R01
HL67871 and 1R01 DE14897 to GD, and 5R01 DK38961 to
SC.
References
[1] Laube DM, Yim S, Ryan LK, Kisich KO, Diamond G. Antimicrobial
peptides in the airway. Curr TopMicrobiol Immunol 2006;306:153–82.
[2] Singh PK, Tack BF, McCray Jr PB, Welsh MJ. Synergistic and additive
killing by antimicrobial factors found in human airway surface liquid.
Am J Physiol Lung Cell Mol Physiol 2000;279(5):L799–805.
[3] BraffMH,Gallo RL. Antimicrobial peptides: an essential component of
the skin defensive barrier. Curr Top Microbiol Immunol 2006;306:
91–110.
[4] Ramanathan B, Davis EG, Ross CR, Blecha F. Cathelicidins:
microbicidal activity, mechanisms of action, and roles in innate
immunity. Microbes Infect 2002;4(3):361–72.
[5] Zanetti M, Gennaro R, Scocchi M, Skerlavaj B. Structure and biology
of cathelicidins. Adv Exp Med Biol 2000;479:203–18.
[6] Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL. Control
of the innate epithelial antimicrobial response is cell-type specific and
dependent on relevant microenvironmental stimuli. Immunology
2006;118(4):509–19.
[7] Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, et al. The
human antimicrobial and chemotactic peptides LL-37 and alpha-
defensins are expressed by specific lymphocyte and monocyte
populations. Blood 2000;96(9):3086–93.
[8] Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/
hCAP-18 is expressed in epithelia of the human lung where it has
broad antimicrobial activity at the airway surface. Proc Natl Acad Sci
U S A 1998;95(16):9541–6.
[9] De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, et al.
LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin,
utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to
chemoattract human peripheral blood neutrophils, monocytes, and T
cells. J Exp Med 2000;192(7):1069–74.
[10] Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE,
Borregaard N, et al. The antimicrobial peptide LL-37 activates innate
immunity at the airway epithelial surface by transactivation of the
epidermal growth factor receptor. J Immunol 2003;171(12):6690–6.
[11] Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The
human antimicrobial peptide LL-37 is a multifunctional modulator of
innate immune responses. J Immunol 2002;169(7):3883–91.
[12] Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE.
Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2005;77(4):
451–9.
[13] Zhang L, Parente J, Harris SM, Woods DE, Hancock RE, Falla TJ.
Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob
Agents Chemother 2005;49(7):2921–7.
[14] Hancock RE. The therapeutic potential of cationic peptides. Expert
Opin Investig Drugs 1998;7(2):167–74.
[15] Hancock RE, Patrzykat A. Clinical development of cationic antimi-
crobial peptides: from natural to novel antibiotics. Curr Drug Targets
Infect Disord 2002;2(1):79–83.[16] Zasloff M. Antimicrobial peptides of multicellular organisms. Nature
2002;415(6870):389–95.
[17] Hancock RE. Host defence (cationic) peptides: what is their future
clinical potential? Drugs 1999;57(4):469–73.
[18] Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises
and promises. Int J Antimicrob Agents 2004;24(6):536–47.
[19] Erdag G, Morgan JR. Interleukin-1alpha and interleukin-6 enhance the
antibacterial properties of cultured composite keratinocyte grafts. Ann
Surg 2002;235(1):113–24.
[20] Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin
antimicrobial peptide (CAMP) gene is a direct target of the vitamin
D receptor and is strongly up-regulated in myeloid cells by 1,25-
dihydroxyvitamin D3. FASEB J 2005;19(9):1067–77.
[21] Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like
receptor triggering of a vitamin D-mediated human antimicrobial
response. Science 2006;311(5768):1770–3.
[22] Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al.
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of
antimicrobial peptide gene expression. J Immunol 2004;173(5):
909–12.
[23] Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Torma
H, Stahle M. Vitamin D induces the antimicrobial protein hCAP18 in
human skin. J Invest Dermatol 2005;124(5):1080–2.
[24] Hecker TM, Aris RM. Management of osteoporosis in adults with
cystic fibrosis. Drugs 2004;64(2):133–47.
[25] Barletta F, Dhawan P, Christakos S. Integration of hormone signaling
in the regulation of human 25(OH)D3 24-hydroxylase transcription.
Am J Physiol Endocrinol Metab 2004;286(4):E598–608.
[26] Legarda D, Klein-Patel ME, Yim S, Yuk MH, Diamond G.
Suppression of NF-kappaB-mediated beta-defensin gene expression
in the mammalian airway by the Bordetella type III secretion system.
Cell Microbiol 2005;7(4):489–97.
[27] Ishizawa K, Suzuki T, Yamaya M, Jia YX, Kobayashi S, Ida S, et al.
Erythromycin increases bactericidal activity of surface liquid in human
airway epithelial cells. Am J Physiol LungCellMol Physiol 2005;289(4):
L565–73.
[28] Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM. Salt-
independent abnormality of antimicrobial activity in cystic fibrosis
airway surface fluid. Am J Respir Cell Mol Biol 2001;25(1):21–5.
[29] Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M,
Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung
that is inactivated in cystic fibrosis. Cell 1997;88(4):553–60.
[30] Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway
epithelia fail to kill bacteria because of abnormal airway surface fluid.
Cell 1996;85(2):229–36.
[31] Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha,25-
dihydroxyvitamin D3 target the TNF-alpha pathway to suppress ex-
perimental inflammatory bowel disease. Eur J Immunol 2005;35(1):
217–24.
[32] Diamond G, Russell JP, Bevins CL. Inducible expression of an
antibiotic peptide gene in lipopolysaccharide-challenged tracheal
epithelial cells. Proc Natl Acad Sci U S A 1996;93(10):5156–60.
[33] Schauber J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach
W, et al. Expression of the cathelicidin LL-37 is modulated by short
chain fatty acids in colonocytes: relevance of signalling pathways. Gut
2003;52(5):735–7341.
[34] Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T,
Borregaard N. Wound healing and expression of antimicrobial
peptides/polypeptides in human keratinocytes, a consequence of
common growth factors. J Immunol 2003;170(11):5583–9.
[35] Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Vitamin D
compounds: clinical development as cancer therapy and prevention
agents. Anticancer Res 2006;26(4A):2551–6.
[36] Saiman L, Siegel J. Infection control recommendations for patients
with cystic fibrosis: microbiology, important pathogens, and infection
control practices to prevent patient-to-patient transmission. Am J Infect
Control 2003;31(3 Suppl):S1–S62.
410 S. Yim et al. / Journal of Cystic Fibrosis 6 (2007) 403–410[37] Koczulla AR, Bals R. Antimicrobial peptides: current status and
therapeutic potential. Drugs 2003;63(4):389–406.
[38] Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin
peptide antibiotic gene restores bacterial killing in a cystic fibrosis
xenograft model. J Clin Invest 1999;103(8):1113–7.
[39] Donovan Jr DS, Papadopoulos A, Staron RB, Addesso V, Schulman L,
McGregor C, et al. Bone mass and vitamin D deficiency in adults withadvanced cystic fibrosis lung disease. Am J Respir Crit Care Med
1998;157(6 Pt 1):1892–9.
[40] Lark RK, Lester GE, Ontjes DA, Blackwood AD, Hollis BW, Hensler
MM, et al. Diminished and erratic absorption of ergocalciferol in adult
cystic fibrosis patients. Am J Clin Nutr 2001;73(3):602–6.
